SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Full Name of Registrant)
NOTIFICATION OF LATE FILING
SEC FILE NUMBER:
(Check One): [X] Form 10-K [_] Form 20-F [_] Form 11-K [_] Form
10-Q [_] Form N-SAR
For Period Ended:
[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-QSB
[_] Transition Report on Form N-SAR
For the Transition Period Ended:
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART I - REGISTRATION INFORMATION
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified
in its charter)
(State of incorporation)
(Commission File Number)
(IRS Employer No.)
#3 Bethesda Metro Center
Bethesda, Md 20814
(Address of principal executive offices
and Zip Code)
(Registrant's telephone number, including
PART II - RULE 12b-25(b)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if
[X] (a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject quarterly report on Form 10-K will be filed
on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report
on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date.
PART III - NARRATIVE
The Registrant's quarterly report on Form 10-K could not be
filed within the prescribed time period because the Registrant encountered delays in its preparation of its quarterly financial
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard
to this notification.
(Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13
or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
[X] Yes [_] No
(3) Is it anticipated that any significant changes in results
of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
[_] Yes [X] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Cannabics Pharmaceuticals Inc.
Name of Registrant as Specified in Charter
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
By: Itamar Borochov, Dir, CEO.
Date: November 29
/s/ Itamar Borochov